PPARG and silicosis: During tuberculosis, BLR49653 treatment had the same effect on CD36 expression and FM formation (Mahajan et al., 2012); in silicosis, PPARγ antagonist GW9662 treatment downregulated CD36 expression and inhibited FM formation (Hou et al., 2019).